| Dr Jeffrey R Brown, MD | |
|
445 South Main Street, West Hartford, CT 06110 | |
| (860) 561-7111 | |
| (860) 561-7272 |
| Full Name | Dr Jeffrey R Brown |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 25 Years |
| Location | 445 South Main Street, West Hartford, Connecticut |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306840640 | NPI | - | NPPES |
| 001414359 | Medicaid | CT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 041435 (Connecticut) | Secondary |
| 207QS0010X | Family Medicine - Sports Medicine | 041435 (Connecticut) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Asylum Hill Family Medicine Center, Inc. | 9032016134 | 21 |
| Trinity Health Of New England Provider Network Organization Inc | 0941113567 | 621 |
News Archive
A report of the American Psychological Association (APA) released found evidence that the proliferation of sexualized images of girls and young women in advertising, merchandising, and media is harmful to girls' self-image and healthy development.
The University of Texas MD Anderson Cancer Center and Taiho Pharmaceutical Co., Ltd., today announced a three-year strategic collaboration to accelerate the development of treatments for significant unmet medical needs in oncology, including patients with brain metastases and those with cancers refractory to available therapies.
Aprima Medical Software, a leading developer of electronic health record (EHR), practice management (PM) and revenue cycle management solutions for medical practices, today announced the release of Aprima's Learning Management System (LMS), a series of computer-based educational modules that allows customers to become proficient with its software.
Alkermes, Inc. today announced positive preliminary results from a phase 3 clinical trial of naltrexone for extended-release injectable suspension (XR-NTX) for the treatment of opioid dependence. The six-month phase 3 study met its primary efficacy endpoint and data showed that patients treated once-monthly with XR-NTX demonstrated statistically significant higher rates of clean (opioid-free) urine screens, compared to patients treated with placebo, as measured by the cumulative distribution of clean urine screens (p<0.0002).
Teva Pharmaceutical Industries Ltd. and Xenon Pharmaceuticals Inc. announced today that the US Food and Drug Administration has granted orphan-drug designation to the investigational drug XEN402 being developed for the treatment of pain associated with erythromelalgia.
› Verified 1 days ago
| Entity Name | Trinity Health Of New England Provider Network Organization Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003882812 PECOS PAC ID: 0941113567 Enrollment ID: O20031110000651 |
News Archive
A report of the American Psychological Association (APA) released found evidence that the proliferation of sexualized images of girls and young women in advertising, merchandising, and media is harmful to girls' self-image and healthy development.
The University of Texas MD Anderson Cancer Center and Taiho Pharmaceutical Co., Ltd., today announced a three-year strategic collaboration to accelerate the development of treatments for significant unmet medical needs in oncology, including patients with brain metastases and those with cancers refractory to available therapies.
Aprima Medical Software, a leading developer of electronic health record (EHR), practice management (PM) and revenue cycle management solutions for medical practices, today announced the release of Aprima's Learning Management System (LMS), a series of computer-based educational modules that allows customers to become proficient with its software.
Alkermes, Inc. today announced positive preliminary results from a phase 3 clinical trial of naltrexone for extended-release injectable suspension (XR-NTX) for the treatment of opioid dependence. The six-month phase 3 study met its primary efficacy endpoint and data showed that patients treated once-monthly with XR-NTX demonstrated statistically significant higher rates of clean (opioid-free) urine screens, compared to patients treated with placebo, as measured by the cumulative distribution of clean urine screens (p<0.0002).
Teva Pharmaceutical Industries Ltd. and Xenon Pharmaceuticals Inc. announced today that the US Food and Drug Administration has granted orphan-drug designation to the investigational drug XEN402 being developed for the treatment of pain associated with erythromelalgia.
› Verified 1 days ago
| Entity Name | Asylum Hill Family Medicine Center, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083660096 PECOS PAC ID: 9032016134 Enrollment ID: O20031217000249 |
News Archive
A report of the American Psychological Association (APA) released found evidence that the proliferation of sexualized images of girls and young women in advertising, merchandising, and media is harmful to girls' self-image and healthy development.
The University of Texas MD Anderson Cancer Center and Taiho Pharmaceutical Co., Ltd., today announced a three-year strategic collaboration to accelerate the development of treatments for significant unmet medical needs in oncology, including patients with brain metastases and those with cancers refractory to available therapies.
Aprima Medical Software, a leading developer of electronic health record (EHR), practice management (PM) and revenue cycle management solutions for medical practices, today announced the release of Aprima's Learning Management System (LMS), a series of computer-based educational modules that allows customers to become proficient with its software.
Alkermes, Inc. today announced positive preliminary results from a phase 3 clinical trial of naltrexone for extended-release injectable suspension (XR-NTX) for the treatment of opioid dependence. The six-month phase 3 study met its primary efficacy endpoint and data showed that patients treated once-monthly with XR-NTX demonstrated statistically significant higher rates of clean (opioid-free) urine screens, compared to patients treated with placebo, as measured by the cumulative distribution of clean urine screens (p<0.0002).
Teva Pharmaceutical Industries Ltd. and Xenon Pharmaceuticals Inc. announced today that the US Food and Drug Administration has granted orphan-drug designation to the investigational drug XEN402 being developed for the treatment of pain associated with erythromelalgia.
› Verified 1 days ago
| Entity Name | Hartford Healthcare Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043561301 PECOS PAC ID: 1153573902 Enrollment ID: O20121201000007 |
News Archive
A report of the American Psychological Association (APA) released found evidence that the proliferation of sexualized images of girls and young women in advertising, merchandising, and media is harmful to girls' self-image and healthy development.
The University of Texas MD Anderson Cancer Center and Taiho Pharmaceutical Co., Ltd., today announced a three-year strategic collaboration to accelerate the development of treatments for significant unmet medical needs in oncology, including patients with brain metastases and those with cancers refractory to available therapies.
Aprima Medical Software, a leading developer of electronic health record (EHR), practice management (PM) and revenue cycle management solutions for medical practices, today announced the release of Aprima's Learning Management System (LMS), a series of computer-based educational modules that allows customers to become proficient with its software.
Alkermes, Inc. today announced positive preliminary results from a phase 3 clinical trial of naltrexone for extended-release injectable suspension (XR-NTX) for the treatment of opioid dependence. The six-month phase 3 study met its primary efficacy endpoint and data showed that patients treated once-monthly with XR-NTX demonstrated statistically significant higher rates of clean (opioid-free) urine screens, compared to patients treated with placebo, as measured by the cumulative distribution of clean urine screens (p<0.0002).
Teva Pharmaceutical Industries Ltd. and Xenon Pharmaceuticals Inc. announced today that the US Food and Drug Administration has granted orphan-drug designation to the investigational drug XEN402 being developed for the treatment of pain associated with erythromelalgia.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jeffrey R Brown, MD 445 South Main Street, West Hartford, CT 06110 Ph: (860) 561-7111 | Dr Jeffrey R Brown, MD 445 South Main Street, West Hartford, CT 06110 Ph: (860) 561-7111 |
News Archive
A report of the American Psychological Association (APA) released found evidence that the proliferation of sexualized images of girls and young women in advertising, merchandising, and media is harmful to girls' self-image and healthy development.
The University of Texas MD Anderson Cancer Center and Taiho Pharmaceutical Co., Ltd., today announced a three-year strategic collaboration to accelerate the development of treatments for significant unmet medical needs in oncology, including patients with brain metastases and those with cancers refractory to available therapies.
Aprima Medical Software, a leading developer of electronic health record (EHR), practice management (PM) and revenue cycle management solutions for medical practices, today announced the release of Aprima's Learning Management System (LMS), a series of computer-based educational modules that allows customers to become proficient with its software.
Alkermes, Inc. today announced positive preliminary results from a phase 3 clinical trial of naltrexone for extended-release injectable suspension (XR-NTX) for the treatment of opioid dependence. The six-month phase 3 study met its primary efficacy endpoint and data showed that patients treated once-monthly with XR-NTX demonstrated statistically significant higher rates of clean (opioid-free) urine screens, compared to patients treated with placebo, as measured by the cumulative distribution of clean urine screens (p<0.0002).
Teva Pharmaceutical Industries Ltd. and Xenon Pharmaceuticals Inc. announced today that the US Food and Drug Administration has granted orphan-drug designation to the investigational drug XEN402 being developed for the treatment of pain associated with erythromelalgia.
› Verified 1 days ago
Rachel Elaine Gilbert, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 631 S Quaker Ln, West Hartford, CT 06110 Phone: 860-233-5133 | |
Sharon Stacy Farber, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 1 Abrahms Blvd, West Hartford, CT 06117 Phone: 860-523-3800 Fax: 860-523-3949 | |
Dr. Charity Durham, DO Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2446 Albany Ave Ste 302, West Hartford, CT 06117 Phone: 229-292-1144 | |
Dr. Igor Samegulin, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 74 Park Rd, West Hartford, CT 06119 Phone: 860-218-1725 Fax: 860-218-1727 | |
Mrs. Jennifer Lagosz Conboy, APRN FNP Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1216 Farmington Ave, West Hartford, CT 06107 Phone: 860-561-1007 | |
Mojdeh Heidari, FNP Family Medicine Medicare: Medicare Enrolled Practice Location: 10 Princeton St, West Hartford, CT 06110 Phone: 860-707-5392 |